| Impacts of tissue-type plasminogen activator (tPA) on neuronal survival A Chevilley, F Lesept, S Lenoir, C Ali, J Parcq, D Vivien Frontiers in cellular neuroscience 9, 415, 2015 | 99 | 2015 |
| Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity JP Lopez-Atalaya, BD Roussel, D Levrat, J Parcq, O Nicole, Y Hommet, ... Journal of Cerebral Blood Flow & Metabolism 28 (6), 1212-1221, 2008 | 95 | 2008 |
| Tissue plasminogen activator prevents white matter damage following stroke F Correa, M Gauberti, J Parcq, R Macrez, Y Hommet, P Obiang, ... Journal of Experimental Medicine 208 (6), 1229-1242, 2011 | 94 | 2011 |
| Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl-d-Aspartate Receptors Reduce Stroke Damages and Extend the … R Macrez, P Obiang, M Gauberti, B Roussel, A Baron, J Parcq, F Cassé, ... Stroke 42 (8), 2315-2322, 2011 | 84 | 2011 |
| Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals F Cassé, I Bardou, L Danglot, A Briens, A Montagne, J Parcq, A Alahari, ... Journal of Neuroscience 32 (15), 5186-5199, 2012 | 79 | 2012 |
| Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity J Parcq, T Bertrand, A Montagne, AF Baron, R Macrez, JM Billard, ... Cell Death & Differentiation 19 (12), 1983-1991, 2012 | 67 | 2012 |
| The plasminogen activation system in neuroinflammation A Mehra, C Ali, J Parcq, D Vivien, F Docagne Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1862 (3), 395-402, 2016 | 66 | 2016 |
| Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke F Docagne, J Parcq, R Lijnen, C Ali, D Vivien Stroke 46 (1), 314-320, 2015 | 63 | 2015 |
| Activation of cell surface GRP78 decreases endoplasmic reticulum stress and neuronal death M Louessard, I Bardou, E Lemarchand, AM Thiebaut, J Parcq, J Leprince, ... Cell Death & Differentiation 24 (9), 1518-1529, 2017 | 62 | 2017 |
| Conformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR T Bertrand, F Lesept, A Chevilley, S Lenoir, M Aimable, A Briens, ... Cell Death & Disease 6 (10), e1924-e1924, 2015 | 40 | 2015 |
| HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator BD Roussel, C Mysiorek, A Rouhiainen, A Jullienne, J Parcq, Y Hommet, ... Journal of Cell Science 124 (12), 2070-2076, 2011 | 35 | 2011 |
| Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain J Parcq, T Bertrand, AF Baron, Y Hommet, E Anglès-Cano, D Vivien Journal of Thrombosis and Haemostasis 11 (3), 539-546, 2013 | 30 | 2013 |
| New approaches in nanomedicine for ischemic stroke C Correa-Paz, A da Silva-Candal, E Polo, J Parcq, D Vivien, D Maysinger, ... Pharmaceutics 13 (5), 757, 2021 | 21 | 2021 |
| Optimized tPA: a non-neurotoxic fibrinolytic agent for the drainage of intracerebral hemorrhages R Goulay, M Naveau, T Gaberel, D Vivien, J Parcq Journal of Cerebral Blood Flow & Metabolism 38 (7), 1180-1189, 2018 | 21 | 2018 |
| Nano-zymography using laser-scanning confocal microscopy unmasks proteolytic activity of cell-derived microparticles A Briens, M Gauberti, J Parcq, J Montaner, D Vivien, SM de Lizarrondo Theranostics 6 (5), 610, 2016 | 16 | 2016 |
| Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions A Daruich, J Parcq, K Delaunay, MC Naud, Q Le Rouzic, E Picard, ... Molecular vision 22, 1332, 2016 | 7 | 2016 |
| tPA-NMDAR signaling blockade reduces the incidence of intracerebral aneurysms ER Louet, M Glavan, C Orset, J Parcq, DF Hanley, D Vivien Translational Stroke Research 13 (6), 1005-1016, 2022 | 6 | 2022 |
| F376A/M388A‐solulin, a new promising antifibrinolytic for severe haemophilia A J Parcq, KU Petersen, A Borel‐Derlon, P Gautier, M Ebel, D Vivien, ... Haemophilia 23 (2), 319-325, 2017 | 3 | 2017 |
| O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma AM Thiebaut, ER Louet, M Ianszen, MJ Guichard, DF Hanley, C Gaudin, ... Brain 146 (11), 4690-4701, 2023 | | 2023 |
| Slow release plasminogen activator formulation for use in the treatment of thrombotic or haemorrhagic disease J Parcq, C Gaudin, E Louet, M Guichard US Patent App. 17/998,432, 2023 | | 2023 |
Benoit D RousselINSERM U1237Verified email at cyceron.fr
